

Docket No.: 56032US022

32692

Request for Continued Examination (RCE) Transmittal

Customer Number
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
CENTRAL FAX CENTER

JAN 09 2004

First Named Inventor: Cantor, Adam S.

Application No.: 09/965610

Group Art Unit: 1615

Filed: September 26, 2001

Examiner: Joynes, Robert M.

Title: COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL

This is a Request for Continued Examination (RCE) under 37 CFR § 1.114 of the above-identified application.

1. Submission required under 37 CFR § 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR § 1.116 previously filed on
(Any unentered amendment(s) referred to above will be entered)
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)/Supplemental IDS
- iv. ☐ Other

2. ☐ A Request for Extension of Time is being filed concurrently

3. Fees (The RCE fee under 37 CFR § 1.17(e) is required by 37 CFR § 1.114 when the RCE is filed.)

- a. ☒ The Director is hereby authorized to charge the following fees or credit any overpayments to:
Deposit Account No. 13-3723. A duplicate copy of this letter for fees processing is enclosed.
- i. ☒ RCE fee required under 37 CFR § 1.17(e)
- ii. ☐ Other

Respectfully submitted,

January 9, 2004

Date

By: Ted Ringard

Ted Ringard, Reg. No.: 35,658
Telephone No.: (651) 736-5839

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: (651) 736-3833

Certificate of Mailing or Transmission	
I certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on the date indicated below:	
Sent to Facsimile No.: 703-872-9306	Signature: <i>Carrie M. Arcand</i>
Date: January 9, 2004	Printed Name: Carrie M. Arcand

☒ Customer Number for
Correspondence Address:

32692

32692

PATENT TRADEMARK OFFICE

32692
Customer Number

Patent
Case No.: 56032US022

RECEIVED
CENTRAL FAX CENTER

JAN 09 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: CANTOR, ADAM S.
Application No.: 09/965610 Group Art Unit: 1615
Filed: September 26, 2001 Examiner: Robert M. Joynes
Title: COMPOSITION FOR THE TRANSDERMAL DELIVERY OF
FENTANYL

AMENDMENT AND RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION

To Fax No.: 703-872-9306

I hereby certify that this correspondence is being facsimile transmitted to
the U.S. Patent and Trademark Office on:

Jan. 9, 2004
Date

Carrie M. Arcand
Signed by: Carrie M. Arcand

Dear Sir:

This is in response to the outstanding Office Action, mailed November 19, 2003, in the above-identified application.

This Amendment is believed to be timely submitted. It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Under the provisions of 37 CFR § 1.136(a), Applicant petitions to extend the period for filing a reply in the above-identified application. The requested extension and appropriate fee are as follows (check time period desired):

- ☒ 37 CFR § 1.17(a)(1) - Extension within first month
☐ 37 CFR § 1.17(a)(2) - Extension within second month
☐ 37 CFR § 1.17(a)(3) - Extension within third month
☐ 37 CFR § 1.17(a)(4) - Extension within fourth month.

Please charge any fees due, or credit any overpayment to Deposit Account No. 13-3723.

One copy of this sheet marked duplicate is also enclosed.

Application No.: 09/965610

Case No.: 56032US022

A. Introductory Comment

~~This Amendment and Response, submitted with the filing of a Request for Continued~~
Examination, is responsive to the Final Office Action mailed November 19, 2003, in the above-
identified application. Further examination of the application is now requested.

Amendments to the Claims are reflected in the listing of claims beginning on page 3.

Remarks begin on page 11.